Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/28/2023* -- Results Q4 2022 -- -1.35 --
11/07/2022 -- Results Q3 2022 -1.56 -1.09 -43.24%
08/09/2022 -- Results Q2 2022 -1.02 -1.02 0.36%
05/09/2022 -- Results Q1 2022 -1.01 -1.34 24.44%
02/28/2022 -- Results Q4 2021 -0.95 -0.94 -1.14%
11/08/2021 -- Results Q3 2021 -0.42 -0.72 41.86%
08/10/2021 -- Results Q2 2021 -1.23 -0.74 -66.83%
05/11/2021 -- Results Q1 2021 -3.35 -0.75 -344.4%
*Estimated Date/Time

Earnings

Next Report Date 02/28/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/07/2022
Beat/Miss Upgrade
Return Since 16.80%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing.
URL https://www.beamtx.com
Investor Relations URL https://investors.beamtx.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Feb. 28, 2023 (est.)
Last Earnings Release Nov. 07, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
--
--
--
--
--
-2.39%
-44.43%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-14.29%
-4.08%
-29.44%
10.90%
-35.24%
-26.64%
-6.77%
-26.13%
-14.21%
--
--
89.34%
-25.97%
30.15%
136.8%
-62.13%
-62.22%
-17.46%
-36.06%
616.4%
-41.88%
-80.73%
-73.85%
-13.68%
-95.23%
-86.45%
-62.59%
34.62%
-54.04%
-51.73%
-33.10%
-32.80%
-60.92%
As of November 25, 2022.

Profile

Edit
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing.
URL https://www.beamtx.com
Investor Relations URL https://investors.beamtx.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Feb. 28, 2023 (est.)
Last Earnings Release Nov. 07, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
CGARDX 628.00 USD 6.28%
F00001DTZG 593.00 USD 5.93%
F00001DFE6 552.00 USD 5.52%
F00001C7ZQ 503.00 USD 5.03%
CARKBX 484.00 USD 4.84%
IDNA 8.450M USD 4.75%
ARKG 92.18M USD 4.05%
ARKK 293.20M USD 4.04%
GNOM 7.724M USD 3.81%
EAGB.NO 665188.0 USD 3.68%
EARK.NO 2.843M USD 3.64%
APIGX 220520.0 USD 2.00%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter BEAM Tweets